Blueprint Medicines Corp
DelistedCIK 1597264fmd_0HTQHMF5PRZ1MG51Z6N0DDYVS5Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Mar 31, 2025, 46 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 11 | 28 | 21 | 45 | 67 | 794 | 180 | 204 | 249 | 509 |
| Net interest income | – | – | 3 | 11 | 14 | 7 | 2 | (17) | (19) | – |
| Cost of revenue | – | – | – | – | – | 0 | 18 | 18 | 9 | 20 |
| Gross profit | – | – | – | – | – | 793 | 162 | 186 | 241 | 489 |
| Research and development | 49 | 81 | 145 | 244 | 331 | 327 | 601 | 477 | 428 | 341 |
| Selling, general and administrative | – | – | – | 48 | 96 | 158 | 195 | 237 | 295 | 359 |
| Total operating expenses | 63 | 100 | 173 | 292 | 428 | – | – | – | – | – |
| Interest expense | 1 | 0 | 0 | 0 | – | – | – | – | – | – |
| Other non-operating income (expense) | (1) | 0 | 3 | 10 | 14 | 6 | 1 | (15) | (20) | 146 |
| Income before taxes | – | – | – | (237) | (348) | 315 | (641) | (552) | (506) | (66) |
| Income tax expense | – | – | – | – | – | 1 | 3 | 5 | 1 | 1 |
| Net income from continuing operations | – | – | – | – | – | 314 | (644) | (558) | (507) | (67) |
| Net income | (53) | (72) | (148) | (237) | (348) | 314 | (644) | (558) | (507) | (67) |
| Net income to common shareholders | (56) | (72) | (148) | (237) | (348) | 314 | (644) | (558) | – | – |